Cover Image
市場調查報告書

非典型溶血性尿毒症症候群:全球臨床實驗趨勢

Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) Global Clinical Trials Review, H1, 2017

出版商 GlobalData 商品編碼 349779
出版日期 內容資訊 英文 49 Pages
訂單完成後即時交付
價格
Back to Top
非典型溶血性尿毒症症候群:全球臨床實驗趨勢 Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) Global Clinical Trials Review, H1, 2017
出版日期: 2017年04月30日 內容資訊: 英文 49 Pages
簡介

本報告提供非典型溶血性尿毒症症候群治療藥相關臨床實驗趨勢調查,提供臨床實驗數量及受驗人數,各階段狀況,有潛力的企業,開發中的治療藥資訊,臨床實驗簡介等相關的系統性資訊。

本報告概要

各地區的臨床實驗情形

  • 各國臨床實驗數量和平均實驗人數
    • 亞太地區主要5國的臨床實驗數量
    • 歐洲主要5國的臨床實驗數量
    • 北美主要國家的臨床實驗數量

G7各國臨床實驗數量:消化器官系統疾病治療藥臨床實驗上非典型溶血性尿毒症症候群的比例

G7各國的各階段臨床實驗數量

G7各國臨床實驗數量:各進展狀況

各階段臨床實驗數量

  • 進行中的臨床實驗:各階段

各進展狀況臨床實驗數量

各評估項目臨床實驗數量

一定期間所採用的實驗對象

贊助商類別的臨床實驗數量

有潛力的贊助商

  • 非典型溶血性尿毒症症候群治療藥臨床實驗主要的參與企業

有潛力的藥劑

最新臨床實驗新聞

臨床實驗簡介概要

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

GlobalData's clinical trial report, "Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) Global Clinical Trials Review, H1, 2017" provides an overview of Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) clinical trials scenario. This report provides top line data relating to the clinical trials on Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

Table of Contents

Table of Contents 2

  • List of Tables 3
  • List of Figures 4
  • Report Guidance 5
  • Clinical Trials by Region 6
  • Clinical Trials and Average Enrollment by Country 7
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
  • Top Five Countries Contributing to Clinical Trials in Europe 11
  • Top Countries Contributing to Clinical Trials in North America 12
  • Clinical Trials by G7 Countries: Proportion of Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) to Gastrointestinal Clinical Trials 13
  • Clinical Trials by Phase in G7 Countries 15
  • Clinical Trials in G7 Countries by Trial Status 16
  • Clinical Trials by E7 Countries: Proportion of Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) to Gastrointestinal Clinical Trials 17
  • Clinical Trials by Phase 19
  • In Progress Trials by Phase 20
  • Clinical Trials by Trial Status 21
  • Clinical Trials by End Point Status 22
  • Subjects Recruited Over a Period of Time 23
  • Clinical Trials by Sponsor Type 24
  • Prominent Sponsors 25
  • Top Companies Participating in Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) Therapeutics Clinical Trials 27
  • Prominent Drugs 28
  • Latest Clinical Trials News on Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) 29
  • Mar 27, 2017: Omeros to Present Results from Dose-Ranging Stage of OMS721 Clinical Trial in Atypical Hemolytic Uremic Syndrome at World Congress of Nephrology 29
  • Clinical Trial Profile Snapshots 30

Appendix 46

  • Abbreviations 46
  • Definitions 46
  • Research Methodology 47
  • Secondary Research 47
  • About GlobalData 48
  • Contact Us 48
  • Source 49

List of Tables

List of Tables

  • Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) Therapeutics, Global, Clinical Trials by Region, 2017* 6
  • Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 8
  • Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 9
  • Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017* 10
  • Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 11
  • Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) Therapeutics Clinical Trials, North America, Top Countries, 2017* 12
  • Proportion of Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) to Gastrointestinal Clinical Trials, G7 Countries (%), 2017* 14
  • Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 15
  • Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 16
  • Proportion of Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) to Gastrointestinal Clinical Trials, E7 Countries (%), 2017* 18
  • Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) Therapeutics, Global, Clinical Trials by Phase, 2017* 19
  • Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 20
  • Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) Therapeutics, Global, Clinical Trials by Trial Status, 2017* 21
  • Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) Therapeutics Clinical Trials, Global, by End Point Status, 2017* 22
  • Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 23
  • Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 24
  • Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 26
  • Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 27
  • Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 28

List of Figures

List of Figures

  • Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) Therapeutics, Global, Clinical Trials by Region (%), 2017* 6
  • Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 7
  • Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 9
  • Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2017* 10
  • Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017* 11
  • Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) Therapeutics Clinical Trials, North America, Top Countries (%), 2017* 12
  • Proportion of Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) to Gastrointestinal Clinical Trials, G7 Countries (%), 2017* 13
  • Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 15
  • Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 16
  • Proportion of Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) to Gastrointestinal Clinical Trials, E7 Countries (%), 2017* 17
  • Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) Therapeutics, Global, Clinical Trials by Phase (%), 2017* 19
  • Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) Therapeutics, Global, Clinical Trials In Progress by Phase, 2017* 20
  • Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) Therapeutics, Global, Clinical Trials by Trial Status, 2017* 21
  • Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 23
  • Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017* 24
  • Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 25
  • Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 27
  • Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 28
  • GlobalData Methodology 47
Back to Top